Related Experiment Video

Updated: Aug 14, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast

Y Ko1, K M Koli, S S Banerji

  • 1Department of Biochemistry and Molecular Biology, Medical College of Ohio, P.O. Box 10008, Toledo, OH 43699-0008, USA.

International Journal of Oncology
|February 10, 1998
PubMed

Insights

Loss of transforming growth factor (TGF)-beta type II receptor (T beta RII) inhibits TGF-beta signaling but does not increase MCF-7 cell malignancy. Restoring T beta RII expression re-sensitizes cells to TGF-beta growth inhibition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The transforming growth factor (TGF)-beta type II receptor (T beta RII) plays a crucial role in TGF-beta signaling, influencing cell growth, differentiation, and extracellular matrix production.
  • Dysregulation of T beta RII is implicated in TGF-beta resistance and tumor progression, making it a key target in cancer research.

Purpose of the Study:

  • To investigate the specific role of T beta RII loss in determining cellular malignancy.
  • To assess whether the absence of functional T beta RII is sufficient to induce malignant properties in TGF-beta-sensitive breast cancer cells.

Main Methods:

  • Transfection of MCF-7 cells (ME24) with a tetracycline-repressible truncated T beta RII (kdT beta RII) construct.
  • Assessment of kdT beta RII expression and its dominant-negative inhibitory effects on TGF-beta 1 signaling (proliferation inhibition, fibronectin induction).
  • Evaluation of cell cycle progression and retinoblastoma (Rb) protein phosphorylation upon inhibition of kdT beta RII expression.

Main Results:

  • Transfected cells (ME24t6) expressed high levels of kdT beta RII, which were reversible by tetracycline.
  • kdT beta RII expression conferred dominant-negative inhibition of TGF-beta 1 effects, rendering cells unresponsive to TGF-beta.
  • Inhibition of kdT beta RII expression restored TGF-beta 1-mediated cell cycle arrest (G1 phase) and Rb hypophosphorylation.
  • Despite T beta RII loss, transfectants did not exhibit increased tumorigenicity compared to parental cells.

Conclusions:

  • Loss of T beta RII function inhibits TGF-beta signaling pathways, including growth inhibition and extracellular matrix stimulation.
  • The absence of functional T beta RII alone is insufficient to confer increased tumorigenicity in this MCF-7 cell model.
  • These findings suggest that other factors beyond T beta RII are critical for the malignant progression associated with T beta RII-expressing and non-expressing cell lines.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...